-

$undefined

N/A

(N/A)

Grace Therapeutics NasdaqCM:GRCE Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Location: 103 Carnegie Center, Princeton, NJ, 08540, United States | Website: https://www.gracetx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

17.34M

Cash

11.06M

Avg Qtr Burn

-3.51M

Short % of Float

0.21%

Insider Ownership

38.39%

Institutional Own.

39.75%

Qtr Updated

12/31/24